FY2026 EPS Estimates for Edesa Biotech Decreased by Analyst

Edesa Biotech, Inc. (NASDAQ:EDSA) – Equities research analysts at Brookline Capital Markets lowered their FY2026 EPS estimates for shares of Edesa Biotech in a report released on Friday, August 14th. Brookline Capital Markets analyst K. Raja now expects that the company will post earnings per share of ($1.98) for the year, down from their prior forecast of ($1.75). Brookline Capital Markets currently has a “Strong-Buy” rating on the stock. The consensus estimate for Edesa Biotech’s current full-year earnings is ($1.66) per share. Brookline Capital Markets also issued estimates for Edesa Biotech’s Q4 2026 earnings at ($0.57) EPS, FY2027 earnings at ($2.46) EPS, FY2028 earnings at ($2.92) EPS, FY2029 earnings at ($2.37) EPS and FY2030 earnings at ($1.26) EPS.

EDSA has been the subject of several other research reports. Wall Street Zen lowered shares of Edesa Biotech from a “sell” rating to a “strong sell” rating in a report on Saturday, August 8th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Edesa Biotech in a research note on Wednesday, June 24th. One equities research analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $5.00.

Edesa Biotech Stock Performance

EDSA opened at $5.65 on Tuesday. The firm’s fifty day moving average is $6.29 and its two-hundred day moving average is $6.43. The firm has a market cap of $54.43 million, a PE ratio of -3.34 and a beta of 1.08. Edesa Biotech has a twelve month low of $0.72 and a twelve month high of $20.32.

Edesa Biotech (NASDAQ:EDSA) last issued its quarterly earnings data on Thursday, August 13th. The company reported ($0.60) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.44) by ($0.16).

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the company. Susquehanna International Group LLP bought a new position in shares of Edesa Biotech during the third quarter worth about $36,000. DRW Securities LLC bought a new stake in Edesa Biotech in the 4th quarter valued at approximately $191,000. State Street Corp acquired a new position in Edesa Biotech during the 4th quarter worth approximately $27,000. Diadema Partners LP acquired a new position in Edesa Biotech during the 4th quarter worth approximately $77,000. Finally, Perceptive Advisors LLC bought a new position in shares of Edesa Biotech during the 1st quarter worth approximately $2,946,000. 5.50% of the stock is owned by institutional investors and hedge funds.

Edesa Biotech Company Profile

Edesa Biotech, Inc is a clinical-stage biotechnology company focused on the discovery and development of next-generation vaccines and immunotherapies. The company leverages a proprietary self-amplifying RNA platform to create candidates designed for both intranasal and injectable administration. Edesa’s approach aims to elicit robust mucosal and systemic immune responses, with applications spanning infectious diseases and immuno-oncology.

Among Edesa’s pipeline programs is a lead intranasal vaccine candidate targeting SARS-CoV-2, currently advancing through early-stage clinical trials.